Results 31 to 40 of about 36,891 (208)

How we treat bleeding associated with direct oral anticoagulants [PDF]

, 2016
Direct oral anticoagulants are at least as effective as vitamin K antagonists for the prevention and treatment of thromboembolism. Unfortunately, differently from vitamin K antagonists, they have the great drawback of lacking specific antidotes in the ...
Franchini, Massimo, Liumbruno, Giancarlo M, Marano, Giuseppe, Pupella, Simonetta, VAGLIO, Stefania   +4 more
core   +1 more source

The influence of residual apixaban on bleeding complications during and after catheter ablation of atrial fibrillation

Journal of Arrhythmia, 2017
Background: The periprocedural protocol for atrial fibrillation (AF) ablation commonly includes anticoagulation therapy. Apixaban, a direct oral anticoagulant, is currently approved for clinical use; however, little is known about the effects of residual
Yutaro Mukai, Kyoichi Wada, Koji Miyamoto, Kazuki Nakagita, Mai Fujimoto, Kouichi Hosomi, Takeshi Kuwahara, Mitsutaka Takada, Kengo Kusano, Akira Oita   +9 more
doaj   +1 more source

Does amiodarone impact on apixaban levels? The effect of amiodarone on apixaban level among Thai patients with non-valvular Atrial Fibrillation.

PLoS ONE
BackgroundApixaban and amiodarone are drugs used for non-valvular atrial fibrillation (NVAF) in routine practice. The evidence about apixaban plasma levels in patients who receive apixaban with amiodarone, including bleeding outcomes, has been limited ...
Sutee Limcharoen, Sarawuth Limprasert, Pornwalai Boonmuang, Manat Pongchaidecha, Juthathip Suphanklang, Weerayuth Saelim, Wichai Santimaleeworagun, Piyarat Pimsi   +7 more
doaj   +1 more source

Evaluation of safety, pharmacokinetics, and pharmacodynamics of apixaban in pediatric subjects at risk of venous or arterial thrombotic disorder

CPT: Pharmacometrics & Systems Pharmacology, 2023
Apixaban is an oral small‐molecule, direct factor Xa (FXa) inhibitor approved in adults for treatment of deep vein thrombosis and pulmonary embolism, and for reducing risk of venous thromboembolism recurrence after initial anticoagulant therapy.
Samira J. Merali, Wonkyung Byon, Yogesh T. Patel, Amira Elsrougy, David Marchisin, Vidya Perera, Weidong Chen, Bing He, Bindu Murthy   +8 more
doaj   +1 more source

In vivo evaluation of the pharmacokinetic interactions between almonertinib and rivaroxaban, almonertinib and apixaban

Frontiers in Pharmacology, 2023
Background: Almonertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is commonly used as a first-line treatment for non-small cell lung cancer (NSCLC) patients with EGFR T790M mutations.
Zhi Wang, Ying Li, Xueru He, Yuhao Fu, Yajing Li, Xin Zhou, Zhanjun Dong   +6 more
doaj   +1 more source

Update on Extended Treatment for Venous Thromboembolism [PDF]

, 2018
The importance of assessing the probability of venous thromboembolism recurrence, a condition that includes deep vein thrombosis and pulmonary embolism, lies in the fact that it is the most important factor in deciding the duration of anticoagulant ...
Del Toro-Cervera, Jorge, Demelo-Rodríguez, Pablo, Llamazares-Mendo, Cristina, Marra, Alberto M, Peñaloza-Martínez, Eduardo, Proietti, Marco, Soria Fernández-Llamazares, Guillermo, Álvarez-Sala Walther, Luis   +7 more
core   +2 more sources

Carbamazepine Induction Impacting Apixaban Concentrations: A Case ReportNovel Teaching Points

CJC Open, 2020
Avoidance of apixaban with carbamazepine (CBZ) is recommended owing to an anticipated reduction in apixaban concentration, although this drug interaction is poorly described. We report a case wherein apixaban concentration was measured before and 2 weeks
Tammy J. Bungard, BSP, PharmD, R. Neil Roberts, MD   +1 more
doaj   +1 more source

Thrombolysis in a stroke patient on dabigatran anticoagulation: case report and synopsis of published cases [PDF]

, 2013
We present the case of an aphasic 77-year-old stroke patient with left distal M1 occlusion who received rt-PA for thrombolysis while on oral anticoagulant treatment with dabigatran (150 mg b.i.d.).
Abruscato, Mario Giovanni Rosario, Baas, Horst, Hövelmann, Susanne, Pfeilschifter, Waltraud   +3 more
core   +2 more sources

Current clinician perspective on non-vitamin K antagonist oral anticoagulant use in challenging clinical cases. [PDF]

, 2020
OBJECTIVE: The evolution of non-vitamin K antagonist anticoagulants (NOACs) has changed the horizon of stroke prevention in atrial fibrillation (SPAF).
Acar, RD, Akgün, T, Camm, AJ, Emren, V, Kanat, S, Karacağlar, E, Kepez, A, Kul, Ş, Tülüce, K, Türk, UÖ, Yakar Tülüce, S, Özel, E, Şimşek, E   +12 more
core   +1 more source

Traumatic Pseudoaneursym of Superficial Temporal Artery in an Octogenarian Patient Under Apixaban Therapy

Hitit Medical Journal, 2020
An 80-year-old female was admitted to the hospital, presenting a pulsatile and painless mass on the right temporal site occurred one month ago following a blunt head trauma.
Sertan Özyalçın, Adem İlkay Diken, Adnan Yalçınkaya, Ufuk Türkmen   +3 more
doaj